FIELD study (Lancet 2007)
Keech et al reported the diabetic retinopathy outcomes of the Fenofibate Intervention and Event Lowering in Diabetes (FIELD) Study. The authors reported a reduction in the need for laser treatment for diabetic retinopathy in patients on fenofibrate compared to controls (hazard ratio 0.69, p=0.0002).
ACCORD Eye Study (NEJM 2010)
The ACCORD study group reported reduction in the rate of progression of diabetic retinopathy with intensive compared to standard glycemic control and with oral fenofibrate compared to placebo (odds ratio 0.60, P=0.006, 6.5% fenofibrate versus 10.2% placebo).
Review of fenofibrate in management of patients with diabetic retinopathy
Neil Sharma, Ju-Lee Ooi, Jong Ong, Douglas Newman. The use of fenofibrate in the management of patients with diabetic retinopathy: an evidence-based review. Australian Family Physician 2015; 44 (6): 367
Review of PPARα agonists
in diabetic retinopathy
Dr. Tomita et al review the mechanisms by which PPARα activation (e.g., by oral fenofibrate) attenuates vascular damage in diabetic retinopathy